Clinical trials in patients with biochemically relapsed prostate cancer

Lin, Amy; Rini, Brian I.; Small, Eric J.

doi:10.1111/j.1464-410x.2006.06124.x

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the modulation of PSA kinetics by treatment has not yet been shown to correlate with a clinical benefit for the patient. Nevertheless, in a recent review, a change in PSA‐DT was suggested as a clinical endpoint in trials for BCR 70. Different clinical endpoints and even different remission criteria make the comparison of study outcomes in PC difficult.…”

Section: Methodsmentioning

confidence: 99%

Immunotherapy with dendritic cells for prostate cancer

Thomas-Kaskel

Waller

Schultze-Seemann

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Radical prostatectomy for prostate cancer is followed by PSA recurrence in up to 40% of patients. One third of patients with biochemical relapse progress to uncurable metastatic disease. Therefore, alternative treatment modalities are needed both in the situation of PSA recurrence and in hormone-refractory disease. Dendritic cells (DC) are the most powerful antigen-presenting cells, able to prime na€ ıve T-cells and to break peripheral tolerance and thus induce tumor immune responses. More than 400 prostate cancer patients have been treated with DC-based immunotherapy to date, and immune responses have been reported in two-thirds of these, resulting in clinical responses in almost half of the patients treated. Most responses, however, were modest and transient. Therefore, mechanisms of treatment failure and possibilities to improve vaccination efficacy are being discussed. ' 2007 Wiley-Liss, Inc.Key words: prostate cancer; immunotherapy; vaccination; dendritic cells Prostate cancer is the most frequently diagnosed malignancy and the second and third leading cause of cancer-related mortality among men in the United States and Europe, respectively.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunotherapy with dendritic cells for prostate cancer

Thomas-Kaskel

Waller

Schultze-Seemann

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Sin embargo, la modulación de la cinética del PSA con tratamiento sistémico no ha mostrado todavía correlación con un beneficio clínico para el paciente. No obstante, en una revisión reciente, se ha sugerido el cambio del PSA-DT como criterio de evaluación en ensayos clínicos de recidiva bioquímica 47 . En general, las diferencias en los criterios de valoración clínica e incluso de los criterios de remisión hacen que sean difíciles las comparaciones de los resultados de los estudios en cáncer de próstata.…”

Section: Elección De Los Criterios Clínicos De Evaluaciónunclassified

Inmunoterapia activa en cáncer de próstata: Revisión con atención especial a las células dendríticas

Thomas-Kaskel

Veelken

2007

Actas Urológicas Españolas

View full text Add to dashboard Cite

Recurrent or metastatic prostate cancer is generally considered an incurable disease. Given the transient benefit from hormone deprivation therapy and limited successes of systemic chemotherapy, alternative treatment modalities are needed both in the situation of PSA recurrence and in hormone-refractory disease. Prostate cancer cells express several tumor associated antigens which are currently being evaluated as targets for active and specific immunotherapy approaches. Dendritic cells (DC) are the most powerful antigen-presenting cells (APC), able to prime naive T cells and to break peripheral tolerance and thus induce tumor immune responses. Close to 1000 prostate cancer patients have been treated with DC-based or other forms of active immunotherapy to date. Vaccination-induced immune responses have been reported in two thirds of DC trials, and favorable changes in the clinical course of the disease in almost half of the patients treated. Most responses, however, were modest and transient. Therefore, mechanisms of treatment failure and possibilities to improve vaccination efficacy are being discussed.

show abstract

Clinical trials in patients with biochemically relapsed prostate cancer

Cited by 2 publications

References 37 publications

Immunotherapy with dendritic cells for prostate cancer

Immunotherapy with dendritic cells for prostate cancer

Inmunoterapia activa en cáncer de próstata: Revisión con atención especial a las células dendríticas

Contact Info

Product

Resources

About